PT - JOURNAL ARTICLE AU - Narang, Ankita AU - Lacaze, Paul AU - Ronaldson, Kathlyn J AU - McNeil, John J AU - Jayaram, Mahesh AU - Thomas, Naveen AU - Sellmer, Rory AU - Crockford, David AU - Stowe, Robert AU - Greenway, Steven C. AU - Pantelis, Christos AU - Bousman, Chad A TI - Whole-genome sequencing analysis of clozapine-induced myocarditis AID - 10.1101/2021.07.26.21261157 DP - 2021 Jan 01 TA - medRxiv PG - 2021.07.26.21261157 4099 - http://medrxiv.org/content/early/2021/07/29/2021.07.26.21261157.short 4100 - http://medrxiv.org/content/early/2021/07/29/2021.07.26.21261157.full AB - One of the concerns limiting the use of clozapine in schizophrenia treatment is the risk of rare but potentially fatal myocarditis. Our previous genome-wide association study and human leucocyte antigen analyses identified putative loci associated with clozapine-induced myocarditis. However, the contribution of DNA variation in cytochrome P450 genes, copy number variants and rare deleterious variants have not been investigated. We explored these unexplored classes of DNA variation using whole-genome sequencing data from 25 cases with clozapine-induced myocarditis and 25 demographically-matched clozapine-tolerant control subjects. We identified 15 genes based on rare variant gene-burden analysis (MLLT6, CADPS, TACC2, L3MBTL4, NPY, SLC25A21, PARVB, GPR179, ACAD9, NOL8, C5orf33, FAM127A, AFDN, SLC6A11, PXDN) nominally associated (p<0.05) with clozapine-induced myocarditis. Of these genes, 13 were expressed in human myocardial tissue. Although independent replication of these findings is required, our study provides preliminary insights into the potential role of rare genetic variants in susceptibility to clozapine-induced myocarditis.Competing Interest StatementCAB is the founder and a shareholder of Sequence2Script Inc and a member of the Clinical Pharmacogenetics Implementation Consortium (CPIC) and Pharmacogene Variation Consortium (PharmVar). The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Funding StatementUniversity of Calgary Cumming School of Medicine, Alberta Childrens Hospital Research Institute, and University of Melbourne Establishment Grant.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The present study was approved by the Melbourne Health Human Research Ethics Committee and University of Calgary Conjoint Health and Research Ethics Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, upon reasonable request.